Clinical trials: SARS (Severe Acute Respiratory Syndrome), open to volunteers
SARS-CoV Infection, Covid19
KIDney Injury in Times of COVID-19 (KIDCOV)
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable.
- Conditions
- SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury
- Trial name
- KIDCOV (NCT04705766)
- Testing
- Urine Collection
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
SARS-CoV-2 Infection, Kidney Transplant Infection
SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
COVID-19 is the pandemic disease caused by the SARS-CoV-2 coronavirus. It is a highly contagious viral disease, the condition of which main clinical symptoms are characterized by fever and respiratory symptoms.
- Trial name
- NCT04494776
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Helio Tedesco Silva Junior
Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
This nationwide, multicenter observational study will establish and improve a hospital-based clinical surveillance and early warning system for respiratory syndrome pathogens.
- Conditions
- Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)
- Trial name
- NCT07694648
- Testing
- Tiered pathogen testing and multi-omics analysis
- Where
- 31 sites in China
- Volunteers
- 2,398 people
- Sponsor
- Huashan Hospital
Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
- Trial name
- TILIA (NCT05624450)
- Testing
- Tozorakimab
- Where
- 473 sites in United States, Argentina and 37 more
- Volunteers
- 3,527 people
- Sponsor
- AstraZeneca
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Participants
Educational VR Game Intervention to Enhance Hygiene Practices in Primary School Children
The goal of this observational study is to investigate if VR game-based educational intervention can enhance primary schoolchildren's compliance with hygiene practices to prevent the transmission of SARS-CoV-2 and other upper…
- Trial name
- NCT07168759
- Testing
- VR game -based education program
- Where
- China
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Severe COVID-19
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
ICU Patients admitted after ARDS due to COVID infection should be weaned from invasive mechanical ventilation as quickly as possible.
- Trial name
- PET-DEXDOCOVID (NCT05233605)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)
Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster
This is a descriptive, open-label, multicenter, non-randomized, uncontrolled phase I clinical study to evaluate the safety, reactogenicity, and immunogenicity of the COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz at doses of 25…
- Trial name
- NCT07640308
- Testing
- Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg
- Volunteers
- 90 people
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study…
- Trial name
- NCT05261139
- Testing
- nirmatrelvir, ritonavir
- Where
- 73 sites in United States, Bulgaria and 5 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
COVID-19
Convalescent Plasma as a Possible Treatment for COVID-19
Patients who are ill with COVID-19 may benefit from receiving convalescent plasma infusions containing antibodies from donors who have recovered from the disease and are proven to no longer be infected.
- Trial name
- NCT04442191
- Testing
- Convalescent plasma
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Illinois Chicago
Hypoxemia, Severe Acute Respiratory Syndrome
Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial
Multicenter, parallel-group, randomized clinical trial comparing the administration of systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days vs no corticosteroid administration among adults…
- Trial name
- STAR (NCT07199192)
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19
The purpose of this study is to look at the safety and effectiveness of PAXLOVID in the real world and not in clinical studies. The study observes patients who have a high chance of getting severe COVID-19 in Korea.
- Trial name
- NCT05890612
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Pfizer
Covid19, SARS-CoV Infection
Imaging Immune Activation in COVID-19
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of [18F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent…
- Trial name
- NCT04815096
- Testing
- [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- CellSight Technologies, Inc.
COVID-19, Corona Virus Infection
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that they can still infect other people.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2
- Trial name
- C-PIC (NCT04448145)
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Columbia University
Influenza Viruses, Respiratory Syncytial Virus (RSV)
ELderly REspiratory VIral Cohort
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and…
- Conditions
- Influenza Viruses, Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2, Human Metapneumovirus (hMPV)
- Trial name
- ELREVI (NCT07813481)
- Testing
- Respiratory viral infection
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Infections
Study of Viral Respiratory Infections
Acute viral respiratory infections are a major public health problem, as they cause mortality especially in pediatric patients, over 65 and those with co-morbidities.
- Trial name
- NCT06764381
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Post-Acute Sequelae of SARS-CoV-2 Infection, Long COVID
Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism
This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency.
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 Infection, Long COVID, Long COVID Fatigue, Long COVID Syndrome
- Trial name
- IVIG-LC (NCT06992401)
- Volunteers
- 50 people
- Sponsor
- Tamara C Tamas
COVID-19
Influence of Nutritional Indices on the Prognosis of Patients With SARS-CoV-2 Infection
With the decline of virulence after the mutation of the SARS-CoV-2 , based on the national life and health and national development needs, the domestic SARS-CoV-2 infection epidemic prevention policy has changed, and the number…
- Trial name
- NCT05835102
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Juan Kang
Healthy Participants
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
- Trial name
- NCT07093580
- Testing
- S-892216-LAI
- Where
- 3 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Shionogi
Immunization, Healthy Volunteers
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60…
- Conditions
- Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization
- Trial name
- NCT07890454
- Testing
- IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sanofi